pubmed-article:8649634 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8649634 | lifeskim:mentions | umls-concept:C0019163 | lld:lifeskim |
pubmed-article:8649634 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:8649634 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
pubmed-article:8649634 | lifeskim:mentions | umls-concept:C1524112 | lld:lifeskim |
pubmed-article:8649634 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
pubmed-article:8649634 | lifeskim:mentions | umls-concept:C1522475 | lld:lifeskim |
pubmed-article:8649634 | lifeskim:mentions | umls-concept:C0442117 | lld:lifeskim |
pubmed-article:8649634 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
pubmed-article:8649634 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:8649634 | pubmed:dateCreated | 1996-7-23 | lld:pubmed |
pubmed-article:8649634 | pubmed:abstractText | To determine whether hepatitis B vaccination given intracutaneously (i.c.) is more effective than intramuscularly (i.m.) in primary non-responding haemodialysis patients. | lld:pubmed |
pubmed-article:8649634 | pubmed:language | eng | lld:pubmed |
pubmed-article:8649634 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8649634 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8649634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8649634 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8649634 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8649634 | pubmed:month | Jan | lld:pubmed |
pubmed-article:8649634 | pubmed:issn | 0931-0509 | lld:pubmed |
pubmed-article:8649634 | pubmed:author | pubmed-author:ChangP CPC | lld:pubmed |
pubmed-article:8649634 | pubmed:author | pubmed-author:van LeerEE | lld:pubmed |
pubmed-article:8649634 | pubmed:author | pubmed-author:van DorpW TWT | lld:pubmed |
pubmed-article:8649634 | pubmed:author | pubmed-author:Schrander-van... | lld:pubmed |
pubmed-article:8649634 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8649634 | pubmed:volume | 11 | lld:pubmed |
pubmed-article:8649634 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8649634 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8649634 | pubmed:pagination | 191-3 | lld:pubmed |
pubmed-article:8649634 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:meshHeading | pubmed-meshheading:8649634-... | lld:pubmed |
pubmed-article:8649634 | pubmed:year | 1996 | lld:pubmed |
pubmed-article:8649634 | pubmed:articleTitle | Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. | lld:pubmed |
pubmed-article:8649634 | pubmed:affiliation | University Hospital Leiden, Kennemer Gasthuis, Haarlem, The Netherlands. | lld:pubmed |
pubmed-article:8649634 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:8649634 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:8649634 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |